These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28602775)

  • 1. Adjuvant capecitabine for HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
    Rashad N; Abdelhamid T; Shouman SA; Nassar H; Omran MA; El Desouky ED; Khaled H
    Clin Breast Cancer; 2020 Jun; 20(3):228-237. PubMed ID: 32005499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
    Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.
    O'Shaughnessy J; Koeppen H; Xiao Y; Lackner MR; Paul D; Stokoe C; Pippen J; Krekow L; Holmes FA; Vukelja S; Lindquist D; Sedlacek S; Rivera R; Brooks R; McIntyre K; Brownstein C; Hoersch S; Blum JL; Jones S
    Clin Cancer Res; 2015 Oct; 21(19):4305-11. PubMed ID: 26041745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva FJ; Hortobagyi GN
    J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
    Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
    Longo F; Mansueto G
    Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials.
    Zhou W; Cao Y; Gou P; Zeng X; Hu X; Lin Z; Ye C; Chen L; Yao G
    Future Oncol; 2021 Dec; 17(35):4993-5002. PubMed ID: 34689590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphocytes prognostic in breast cancer.
    Sklan A
    Lancet Oncol; 2014 Sep; 15(10):e422. PubMed ID: 25328947
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
    He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
    Trials; 2015 May; 16():238. PubMed ID: 26021722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.
    Di Leo A; Moretti E
    J Clin Oncol; 2008 Nov; 26(31):5011-3. PubMed ID: 18768431
    [No Abstract]   [Full Text] [Related]  

  • 18. Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study.
    Kószó R; Sántha D; Büdi L; Erfán J; Győrfy K; Horváth Z; Kocsis J; Landherr L; Hitre E; Máhr K; Pajkos G; Pápai Z; Kahán Z
    Pathol Oncol Res; 2017 Jul; 23(3):505-511. PubMed ID: 27771885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.